Company profile: Cenes
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products, developing and commercializing drugs for pain control, sedation, and other central nervous system disorders.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cenes
Nalu Medical
HQ: United States
Website
- Description: Provider of innovative medical technology solutions for patients with chronic neuropathic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nalu Medical company profile →
Vivoryon Therapeutics
HQ: Germany
Website
- Description: Provider of biopharmaceutical R&D and clinical development focused on small molecule medicines for Alzheimer’s disease and cancer, including varoglutamstat (QPCT inhibitor, Phase 2) and a portfolio of QPCT/L inhibitors, supported by a comprehensive clinical program. Holds a strategic licensing partnership with Simcere for varoglutamstat and a preclinical monoclonal N3pE‑antibody in Greater China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivoryon Therapeutics company profile →
Gilgamesh Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilgamesh Pharmaceuticals company profile →
Tissuemed
HQ: United Kingdom
Website
- Description: Provider of tissue-based therapeutic devices and surgical bioadhesive films, including the first tissue heart valve to gain regulatory approval in Europe. Specializes in adhesive films to prevent air, blood and fluid leaks encountered in surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissuemed company profile →
Jupiter Neurosciences
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting Alzheimer's and rare neurological disorders, including JOTROL, an oral micellar resveratrol formulation designed to deliver therapeutic doses without side effects. The company pursues a pipeline strategy using a Phase I study to enable trials for three rare diseases and mild cognitive impairment to proceed directly to Phase II.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jupiter Neurosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cenes
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cenes
2.2 - Growth funds investing in similar companies to Cenes
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cenes
4.2 - Public trading comparable groups for Cenes
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →